Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May;143(5):559–575. doi: 10.1085/jgp.201311050

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Mercado et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 4. — AngII increases TRPV4 sparklet activity in arterial myocytes. (A) TIRF images of an arterial myocyte before (left) and after (right) application of 100 nM AngII. The traces below each image show the time course of [Ca²⁺]_i in sites 1 and 2. Broken red lines mark the amplitude of elementary and multichannel TRPV4 sparklets, whereas the solid line shows the baseline. (B) Scatter plot of TRPV4 sparklet activity under control conditions and after application of AngII. The red lines are the median values (*, P < 0.05; n = 18; Mann-Whitney test). (C) Bar plot of TRPV4 sparklet site density before and after application of AngII. Data are means ± SEM (error bars; *, P < 0.05, n = 4; two-tailed Student’s t test). (D) Amplitude histogram of TRPV4 sparklets before (white bars) and after AngII (gray bars) application. Data were fit with a Gaussian function with a q-value of 48 nM for control (black line) and AngII (red line) data.